<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372355</url>
  </required_header>
  <id_info>
    <org_study_id>SWUEC-043/2019F</org_study_id>
    <secondary_id>WF10-19-THAI-01</secondary_id>
    <nct_id>NCT04372355</nct_id>
  </id_info>
  <brief_title>Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients</brief_title>
  <official_title>Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Srinakharinwirot University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oxo Chemie(Thailand) Co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Altermed Co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Srinakharinwirot University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study in adult Diabetes Mellitus patients with diabetic foot ulcers and elevated HbA1c who&#xD;
      will receive standard wound treatment in combination with adjuvant therapy WF10 to compare&#xD;
      the change of HbA1c levels at baseline and after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center, Prospective Open-labelled One Group Pretest Posttest Pilot Study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Actual">June 19, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>T2DM patients with DFU and HbA1c &gt; 8.5%</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change at Week 8 in comparison to Baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>The mean change of HbA1c values between Baseline (Week 0) and Week 8 after the initial WF10 treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c change at Week 12 in comparison to Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>The mean change of HbA1c values between Baseline (Week 0) and Week 12 after the initial WF10 treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetic Foot Ulcer (DFU)</condition>
  <condition>Uncontrolled Diabetes With Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Chlorite-based drug WF10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WF10</intervention_name>
    <description>WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.</description>
    <arm_group_label>Chlorite-based drug WF10</arm_group_label>
    <other_name>Immunokine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with Diabetes Mellitus type II&#xD;
&#xD;
          -  Patient male or female 18-80 years old&#xD;
&#xD;
          -  Presence of Diabetic foot ulcer/non-healed stump, starting at least 3 weeks before or&#xD;
             infected wound degree 3-4&#xD;
&#xD;
          -  HbA1c &gt; 8.5%&#xD;
&#xD;
          -  Hematocrit &gt; 30%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Kanofsky performance status &lt; 60&#xD;
&#xD;
          -  Patient with ABI (Ankle Brachial index) &lt; 0.4&#xD;
&#xD;
          -  Patient who receive steroid ,chemotherapeutic drug&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Patient had a history of organ transplantation, and using immunosuppressive drug&#xD;
&#xD;
          -  Patient with end-stage renal disease requiring hemodialysis, or history of G6PD or&#xD;
             severe thalassemia, or ischemic heart disease, Congestive heart failure, Heart&#xD;
             arrhythmia&#xD;
&#xD;
          -  Patient who is participating in another clinical study or have done it in the past 30&#xD;
             days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narongchai Yingsakmongkol, MD, FRCST</last_name>
    <role>Principal Investigator</role>
    <affiliation>Srinakharinwirot University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HRH Princess Maha Chakri Sirindhorm Medical Center</name>
      <address>
        <city>Ongkharak</city>
        <state>Nakhon Nayok</state>
        <zip>26120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Srinakharinwirot University</investigator_affiliation>
    <investigator_full_name>Narongchai Yingsakmongkol</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>DFU</keyword>
  <keyword>WF10</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

